Drug intelligence / Profile preview

Nalu-0013

Development stage: Preclinical
Lead developer: Nalu Bio
Modality: Small Molecules

Overview

Nalu-0013 is a small molecule drug candidate being developed by Nalu Bio for the treatment of metabolic and immune-related disorders. It functions by targeting G protein-coupled receptors (GPCRs) within the endocannabinoid system (ECS). Nalu Bio utilizes a chemistry-based approach to develop high-purity, non-cannabinoid-derived molecules that precisely modulate the ECS, aiming to provide therapeutic benefits while avoiding the side effects associated with traditional cannabinoid therapies. As of early 2024, Nalu-0013 is in the basic research stage of development.

Targets

CB (Cannabinoid receptors)

Beyond the preview

Go deeper on Nalu-0013.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nalu-0013.

Explore the full profile